oep introduction 2010 eng

ativity

Introduction of Orient Europharma

ativity

General Information

Financial Performance

Business Unit Performance

Business Development

ativity

GENERAL INFORMATION

ativity

OEP near term Strategy

★ Diversity in Product Portforlios

Presence in Major Asian Countries★

★ Collaboration in Product Dev

ativity

Major Business Segment

Oncology

Nutricare

Consumer Health

Cosmetic

Pharma

Orient Pharma

ativity

Headquarters & Subsidiaries of

ORIENT EUROPHARMA CO., LTD

Subsidiaries: Hong Kong

Philippines

Malaysia

Singapore

Headquarters: Taipei, Taiwan

ativity

Infant Nutrition

OEP’s Own－Karihome®

Goat & Cow Series milk powder

Revenue Contribution from Division

Cosmetic

Nutrition Ethical

OtherAdult NutritionOEP’s KariMed®

Adult health supplements

Aesthetic & Skincare products

Licensing-in & Self Development

ativity

Our Sales Force Overview

Countries /Region

Hospital

Specialty

Aesthetic

Taiwan

Singapore

Malaysia

Hong Kong

Philippines

ativity

Worldwide Partners1982

20082009

2009 2009 2009

ativity

FINANCIAL PERFORMANCE

ativity

2009 Financial Summary

2009 Total Net Revenue USD $ 121M，10% growth over 2008

2009 EPS $4.04 ， highest among all listed Taiwan Pharmaceutical company

2009 vs 2008 Reveneue

•Singapore +16%

•Philippines +11% ( Ranked No. 26 based on IMS revenue)

•Malaysia +5%

•Hong Kong +7%

•China +75%

ativity

RevenueUnit：

Million (USD)

2005 2006 2007 2008 2009

Taiwan 64 70 83 93 100

Oversea 6 9 14 18 21

Total 71 79 96 112 121

Oversea

Taiwan

ativity

Net Profit After Tax

2005 2006 2007 2008 2009

Net Profit

After Tax3,806,500 4,147,250 5,025,969 7,152,031 8,661,969

Unit：Million (USD)

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

9,000,000

ativity

Earning Per Share

2005 2006 2007 2008 2009

EPS2.62 2.64 2.83 3.45 4.04

Unit：Dollar (TWD)

ativity

Leading Company In Taiwan

ativity

Only Local among Fastest Growth

ativity

Top 10 Among Local MNF

ativity

Top 2 in Mid-sized company in PHL

ativity

BUSINESS UNIT PERFORMANCE

ativity

Nutricare Highlights

2009 AC Nielson survey ranked，OEP’s Karihome milk powder series highest in market share 。

Ranked top 3 in Infant supplementary Food segment。

5% Market share in Special Dietary Formulae。

ativity

Future Strategy & Direction

Interim Strategy /Market Development：

Multiple Branding

New Product Development:

Focus on Infant nutritional Need

Expansion on Special dietary product line

Market Development:

Cont. Expansion in Asia Market

Synergy on promotional resource & standardizing product image.

ativity

Pharmaceutical

Product Portfolio focused

cardiovascular

Metabolism

Respiratory

Woman’s Health

Central Nervous System

Main drive in 2009 revenue in two major segment : Cardiovascular & Metabolism 。

ativity

Future Strategy:

Continue in expanding market share in cardiovascular & metabolism market。

Continue expansion in Self-payment or not reimbursement market。

2010 Product Portfolio :

Q1 :First generic in Immuno suppressant for organ transplant patients。

Q2: Foster for treatment of Asthma 。

Q3: Collaboration with Japanese Pharma for fast acting DM Type II Disease。

Market Planning:

Current Product: Expansion to Hospital/Clinic channel。

New Product: Synergy with current product to speed up Listing。

ativity

Oncology

Navelbine IV / Oral for Non-small cell lung cancer & Breast cancer

Nominated by Pierre Fabre as the best performing Territory among Pierre Fabre subsidiary & Licensee for two consecutive years 2008 & 2009

ativity

Active collaboration with partners in International clinical trial to provide the best treatment to the cancer patients in Asia Pacific

Cancer Treatment

Best Supportive Care

Product under Ongoing registration or Clinical Trial：

Loramyc® : Oral Candidiasis

Nanoplatin®:Nano technology of Cisplatin for Pancreatic Cancer.

Multikine®:Head & Neck Cancer Phase III trial scheduled to commenced in Q3, 2010.

ativity

COSMETIC Sole Distributor for the world reknown Brand︰

Q-MED︰RESTYLANE ( Hyaulronic Acid Injectable)

Pierre Fabre (France)︰ADERMA，DUCRAY

Dermofarm (Spain)︰CUMLAUDE

Noevir (Japan)︰NOV

Channel Coverage: Hospital, Clinic & Pharmacy。

Established in 2002，CAGR : Two digit growth 。

ativity

2010 Promotional Strategy：

Expansion in Channel

Introduce new skin care concept from Europe : Organic product

Introduce new aesthetic technology

Total Solution！Not just product but total skin care services from in to out

ativity

Consumer HealthcareMain Concept : Product Development aroud:

Organic Health supplement

Oral Care

Adult Nutrition in Milk & Cereal

Health Supplement – A series of product under (KariMed) developed for Skin whitening & Anti-aging 。

Oral Care- (BUCCOTHERM) make from Natural Spring Water from France以; Total Oral care from Infant to Adult. Due to its unique taste and chemical free feature is the first choice in oral care for infants。

Adult Nutrition in Milk & Cereal– (Vitaglow )series of milk and cereal co-development Lactalis &Global Health。

ativity

Key Strategy in Expansion

Brand Recognition、Channel & Profitbility：

Inc Distributor

Inc Medical activities

Innovation

ativity

BUSINESS DEVELOPMENT

ativity

Phase 1 Phase II Phase III Registration Marketed

Ella (HRA Pharma)

Glufast (Kissei)

Hylase(reimser)

L o r a m y c( H a n d o k )

B r o n u c k( S e n j u )

Vido (Senju)

N a n o p l a t i n(NanoCarrier)

M u l t i k i n e( C e l - S c i )

Licensing - Pipeline Information

ativity

PRODUCTS AVAILABLE FOR EXPORT

ATC Code

•A02

•A10

•C03

•G04

•L04

•N05

NCE/NF/Generic

•Generic

Compound

•Granisetron

•Glibenclamide + Meformin

•Metolazone

•Alfuzosin

•Mycophenolate

•Zeleplon

Dosage

•1mg/ml

•1mg/3ml

•2.5mg + 500mg

•5mg + 500mg

•0.5mg

•10mg SR

•250mg

•10mg

Indication

•Supportive Care Therapy

•Type II DM

•Diuretic

•BPH

•Immunosuppressant

•Insomnia

ativity

2010 2011 2012 2013 2014 2015

Rifampin-IsoniazidCapsules

ParoxetineCR Tablets

PitavastatinFC Tablets

VancomycinCR Capsules

VancomycinIR Capsules

LansoprazoleODT

Miglitol FC Tablets

ZaleplonDro-Release

R&D Developmental Pipeline - 1

ativity

Oxybutynin/Clonidine

OxybutyninXL Tablets

Trospium XR Capsules

RanolazineER Tablets

RizatriptanODT

Nelfinavir/

DMC Capsules

FenofibrateTablets

Zaleplon10mg

Tablets

2010 2011 2012 2013 2014 2015

ativity

NelfinavirCapsules

Diltiazem-180 XR

Diltiazem-90 XR

PaliperidoneER Tab

Methy-lphenidateCapsules

RivastigminePatch

Isoniazid

2010 2011 2012 2013 2014 2015

ativity

Manufacturing

Orient Pharma

ativity

In-house formulation TechnologiesTwo-Stage Hot-Melt Filling Technology

Transdermal Drug Delivery Technology

Duo-Release Drug Delivery System

Matrix-Controlled Release Drug Delivery System

ODT Drug Delivery System

Fast Release Modified Release

BarrierFast Release Modified Release

a. “CONTROLLED RELEASE OF HYPNOTIC AGENTS” pending. Characteristics: For APIs of low aqueous solubility and to be absorbed systemically.

b. “SUSTAINED DELIVERY OF ANTIBIOTICS” pending.

Characteristics: For APIs of high aqueous solubility and not to be absorbed.

ativity

Project Utilizing Duo – Release System

Partner Product

DURECT (Cupertino, USA) Indication: ADHD

University of Southern California (USC)

Indication: Cancer

Summit PLC (UK)Indication: Sialorrhoea

ativity

Orient Pharma Facility

Location : Central Science Park

Land Area : 15,200 sq. m (163,400 sq.ft)

Plant I : 1,154 sq. m (12,400 sq. ft)

Plant II : 3 floors with 13,500 sq. m (145,100 sq. ft)

Utility Building : 630 sq. m (6,770 sq. ft )

Design Criteria : FDA, PIC/s & Japanese Standard

ativity

Location

Taipei

Hu Wei Plant

Airport to Taipei: 35 km (22 mi)

Taipei to Taoyuan: 40 km (25 mi)

Taipei to Huwei: 220 km (138 mi)

60 minutes by high speed railway

from Taipei to Huwei

Taoyuan Plant

ativity

Construction Schedule

2008/12 Ground

breaking

2010/03 Plant I ready

for operation

2010/05 Bio-batch

production

2010/10 Plant II

ready for operation

ativity

Landscape

PASS BOX

Plant II

Warehouse

QC Lab

Utility building

ativity

Solid Dosage Forms

Tablets: Sugar Coated, Film Coated

Hard Shell Capsule

1, 2 or 3 Stages Hot Melt Filling ;

Hard Shell IR or MR Semisolid capsule

ativity

Equipment

Machine

Super mixer

Fluid-bed dryer

High-speed tabletting press machine

High-speed doulbe layer tabletting press

machine

Super Coater

2-Stage Hot Melt Capsule filling

machine

Capacity

190~495 L

28 station 50k~84k tablet/hr

61 station 100k~500k tablet/hr

120~150 kg/batch

30k cap/hr

Yuan Cheng

VG 600

GPCG PRO 120

YC-SC-125FS

Diameter

Max.16mm

Max. 25mm

ativity

Annual Capacity

Tablet: 800 million

Capsule: 320 million

Hot Melt Capsule: 60 million

ativity

Services

Production/Validation

Analysis/Validation

Stabilities Study

Clinical trial supply Prod & Packaging

CMC Documentation

Distribution

Purchasing

ativity

THANK YOU!

oep introduction 2010 eng

Documents

ny.havsfrun.se.temp-url.seny.havsfrun.se.temp-url.se/sites/default/files/... ·...

oep presentation

orenda introduction 12 eng

taxi 2.0 oep

rankwave connect introduction eng

pluntz oep presentation

bisl introduction eng

introduction matlab eng

oep dj radio

jsp eng introduction

1972 oep steminfla

oep team tech_preneurs

introduction to contributing to oer/oep

skillout.com – oep

ormulario notarial - oep

globe testing introduction (eng)

selectex standford oep

ipenable oep

crowdkeys oep partnership

l00 introduction eng [algorithms]